Human Genome Epidemiology Literature Finder
Records 1 - 4 (of 4 Records) |
Query Trace: Lung Neoplasms and EPHB4[original query] |
---|
XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2012 Jan 7 (1): 219-26. Pietanza M Catherine, Lynch Thomas James, Lara Primo N, Cho John, Yanagihara Ronald H, Vrindavanam Nandagopal, Chowhan Naveed Mahfooz, Gadgeel Shirish M, Pennell Nathan A, Funke Roel, Mitchell Ben, Wakelee Heather A, Miller Vincent |
Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2012 May 7 (5): 856-65. Pietanza M Catherine, Gadgeel Shirish M, Dowlati Afshin, Lynch Thomas J, Salgia Ravi, Rowland Kendrith M, Wertheim Michael S, Price Katharine A, Riely Gregory J, Azzoli Christopher G, Miller Vincent A, Krug Lee M, Kris Mark G, Beumer Jan H, Tonda Margaret, Mitchell Ben, Rizvi Naiyer |
EphB4 gene polymorphism and protein expression in non-small-cell lung cancer. Molecular medicine reports 2012 Aug 6 (2): 405-8. Zheng Ming-Feng, Ji Yong, Wu Xiao-Bo, Ye Shu-Gao, Chen Jing- |
EphB4 as a Novel Target for the EGFR-Independent Suppressive Effects of Osimertinib on Cell Cycle Progression in Non-Small Cell Lung Cancer. International journal of molecular sciences 2021 8 22 (16): . Nanamiya Ren, Saito-Koyama Ryoko, Miki Yasuhiro, Inoue Chihiro, Asavasupreechar Teeranut, Abe Jiro, Sato Ikuro, Sasano Hirono |
- Page last reviewed:Feb 1, 2024
- Content source: